Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: WAT stock price vs DHR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Implied fair value · at WAT's multiple
Needs WAT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Waters Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
WAT vs A
BIO-RAD LABORATORIES, INC.
WAT vs BIO
THERMO FISHER SCIENTIFIC INC.
WAT vs TMO
BRUKER CORP
WAT vs BRKR
BIO-TECHNE Corp
WAT vs TECH
ILLUMINA, INC.
WAT vs ILMN
JOHNSON & JOHNSON
WAT vs JNJ
ABBOTT LABORATORIES
WAT vs ABT
LOEWS CORP
WAT vs L
BERKSHIRE HATHAWAY INC
WAT vs BRK-B
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe WAT can sustain its faster 7.0% revenue growth and 23.7% ROIC while preserving its 25.4% operating margin, then holding or modestly accumulating can be justified because the premium valuation is supported by superior operating quality; otherwise, the stock’s position above DHR-implied and DCF ranges argues for caution.
WAT’s current price of $377.31 is above DHR implied range of $155.75 to $252.70 and far above the DCF range of $77.39 to $104.70, suggesting the market is already paying for stronger fundamentals. Against its own historical band of $339.58 to $415.04, WAT sits in the upper half, with the stated P/E-based implied price of $415.44 implying only 10.1% upside.
Supporting Metrics
